A case of immune-mediated encephalitis related to daclizumab therapy. (April 2019)

• Record Type: Journal Article
• Authors: Devlin, Michael; Swayne, Andrew; Newman, Martin; O'Gorman, Cullen; Brown, Helen; Ong, Benjamin; Robertson, Thomas; Airey, Caroline; Blum, Stefan
• Is Part Of: Multiple sclerosis. Volume 25:Number 5(2019)
• Page Start: 750
• Page End: 753
• Publication Date: 2019-04
• Subjects: Daclizumab -- encephalitis -- eosinophilic reaction -- drug reaction; Central nervous system -- Diseases -- Periodicals; Myelin sheath -- Diseases -- Periodicals; Inflammation -- Periodicals; Multiple sclerosis -- Periodicals; Central Nervous System Diseases -- Periodicals; Demyelinating Diseases -- Periodicals; Inflammation -- Periodicals; Multiple Sclerosis -- Periodicals; Système nerveux central -- Maladies -- Périodiques; Gaine de myéline -- Maladies -- Périodiques; Inflammation (Pathologie) -- Périodiques; Sclérose en plaques -- Périodiques; Electronic journals; 616.834005
• DOI: 10.1177/1352458518792403
• Languages: English
• ISSNs: 1352-4585

Abstract

This report will detail a case of immune-mediated encephalitis in the context of daclizumab therapy. Daclizumab is a humanised monoclonal antibody which, prior to its recent worldwide withdrawal due to safety concerns, was utilised as a disease-modifying therapy in relapsing-remitting multiple sclerosis. The withdrawal of this therapy was prompted by concerns over 12 cases of serious immune-mediated adverse reactions in the central nervous system. We report an additional case, including clinical data and results of neuroimaging, cerebrospinal fluid (CSF) examination and brain biopsy.